SpePharm
SpePharm is an Amsterdam-based specialty pharmaceutical company founded in 2006 that acquires, registers, and markets medicines across Europe on behalf of originator and specialty-pharma rights-holders via licensing, acquisition, and special-purpose-vehicle structures.
- Company typePrivate
- Founded1906
- HeadquartersAmsterdam, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
What SpePharm does
SpePharm is a privately held, Amsterdam-based specialty pharmaceutical company founded in 2006 that operates a pan-European platform for acquiring, registering, and marketing medicines. Its stated value proposition is providing originator and specialty-pharma rights-holders with ready-made regulatory and commercial infrastructure across multiple EU jurisdictions — a model typically used to commercialize products whose originators lack a direct European footprint or wish to monetize ex-US assets through licensing, acquisition, or special-purpose-vehicle (SPV) structures.
The core operating asset is the company's portfolio of marketing authorizations and country-level regulatory dossiers across Europe, supported by a small, centralized team of 11–50 employees. SpePharm runs an SPV/licensing-based business-development model managed by a C-suite consisting of Jean-François Labbé (Managing Director & CEO), Caroline Dumas (Chief Medical Officer), and Neil L. Brown (Chief Business Officer). In 2008 the company raised approximately $38.7M from a syndicate of healthcare-specialist investors — Paul Capital, Signet Healthcare Partners, and TVM Capital — to fund product acquisitions and European buildout.
The revenue model is one-time licensing and product-sale income from in-licensed or acquired pharmaceutical assets sold through European distribution channels (hospitals, retail pharmacy, and specialty wholesalers). Pricing is not publicly disclosed. The customer base is fragmented at the end-user level — healthcare providers and patients in gastroenterology, hepatology, and adjacent specialist therapy areas — although the underlying source material conflates SpePharm's profile with that of a much larger European pharma group (Norgine: founded 1906; 1,400+ employees; €500M+ net product sales), so SpePharm-specific commercial scale remains unclear from the input.
SpePharm firmographics
Firmographics- Name
- SpePharm
- Legal name
- Norgine
- Website
- https://spepharm.com
- Company type
- Private
- Founded year
- 1906
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SpePharm is an Amsterdam-based specialty pharmaceutical company founded in 2006 that acquires, registers, and markets medicines across Europe on behalf of originator and specialty-pharma rights-holders via licensing, acquisition, and special-purpose-vehicle structures.
- Ownership category
- akta.pro rank
Where SpePharm is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
SpePharm business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Pharmaceutical product sales: Net product sales of pharmaceutical products across multiple specialist therapy areas including gastroenterology and hepatology
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
SpePharm product offering
Product offeringCore offering
SpePharm is a pharmaceutical company focused on acquiring, registering and marketing medicines throughout Europe. The firm operates as a specialty pharmaceutical partner that leverages licensing, acquisition, and special purpose vehicle (SPV) arrangements to bring innovative medicines to European patients, with emphasis on gastroenterology and hepatology therapeutic areas.
Differentiator
Problem solved
Functional benefit
Products and services
- Specialty pharmaceutical products (gastroenterology and hepatology) Acquired, registered and marketed pharmaceutical products targeting gastroenterology and hepatology conditions, delivered to healthcare providers and patients across Europe through partnership-driven commercialization.
Companies that use SpePharm
Customer profileSegments1 record
Ideal customer profiles2 records
SpePharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
SpePharm partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Partner organizations (unspecified)coreNorgine has a strong global network of partnerships enabling the company to acquire, develop and commercialize innovative products. The company partners in multiple ways including licensing, acquisition, and special purpose vehicles (SPV).
Scale indicators4 records
Recent moves4 records
Expansion highlights4 records
SpePharm competitors and assessment
Company assessmentDirect peers
- Norgine: Norgine is a leading European specialist pharmaceutical company focused on gastroenterology and hepatology with €500M+ revenue. Most directly comparable to SpePharm given the data overlap and apparent partnership/acquisition relationship, sharing therapeutic focus and European specialty pharma model.
- Almirall: Almirall is a European specialty pharmaceutical company headquartered in Spain, focused on dermatology and gastroenterology. Comparable to SpePharm through its European specialty pharma positioning, focus on GI-related therapy areas, and asset-light commercial model.
- Recordati: Recordati is a European specialty pharmaceutical company with operations across multiple therapeutic areas including gastroenterology. Comparable to SpePharm in its European focus, specialty pharma model, and history of acquiring niche products for distribution across European markets.
- Dr. Falk Pharma: Dr. Falk Pharma is a European specialty pharmaceutical company specializing exclusively in gastroenterology and hepatology products. Highly comparable to SpePharm in therapeutic area focus, European commercial presence, and specialty pharma approach.
- Vifor Pharma: Vifor Pharma is a Swiss specialty pharmaceutical company focused on iron deficiency, nephrology, and gastroenterology. Comparable to SpePharm through its European specialty pharma model and concentration in gastroenterology-adjacent therapy areas.
- Swedish Orphan Biovitrum (Sobi): Sobi is a European specialty biopharmaceutical company focused on rare diseases and specialty therapeutic areas. Like SpePharm, it pursues an in-licensing and specialty commercialization model with strong European distribution capabilities and concentrated therapeutic focus.
Broad incumbents
- Shire (now Takeda): Shire was a leading specialty pharmaceutical company focused on rare diseases and specialty therapies before its acquisition by Takeda. Comparable to SpePharm in its asset-light specialty pharma model and European commercial footprint, though operating at significantly greater scale.
- Ipsen: Ipsen is a European specialty pharmaceutical company with strong presence in gastroenterology, oncology, and neuroscience. Comparable to SpePharm in European specialty pharma focus and therapeutic alignment in gastroenterology, though operating at significantly larger scale.
Emerging players
- Cosmo Pharmaceuticals: Cosmo Pharmaceuticals is a specialty pharmaceutical company focused on gastrointestinal diseases and dermatology with European operations. Comparable to SpePharm through its GI therapy focus and specialty pharma model with partner-driven commercialization.
- Stallergenes Greer: Stallergenes Greer is a specialty biopharmaceutical company focused on allergen immunotherapy. Comparable to SpePharm as a European specialty pharma with focused therapeutic area positioning, though serving a different therapeutic category.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
SpePharm social profiles
Digital presenceSpePharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
SpePharm leadership team
Management profileNumber of profiles
Profiles3 records
SpePharm funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SpePharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SpePharm
What does SpePharm do?
SpePharm is a pharmaceutical company focused on acquiring, registering and marketing medicines throughout Europe. The firm operates as a specialty pharmaceutical partner that leverages licensing, acquisition, and special purpose vehicle (SPV) arrangements to bring innovative medicines to European patients, with emphasis on gastroenterology and hepatology therapeutic areas.
Is SpePharm a public or private company?
SpePharm is a private company. It is classified as venture growth investor backed and is currently operating.
When was SpePharm founded?
SpePharm was founded in 1906. It employs 11 to 50 people.
Where is SpePharm based?
SpePharm is headquartered in Amsterdam, Netherlands, in the Europe region.
How does SpePharm make money?
One revenue line is on record: pharmaceutical product sales.
Who are SpePharm's main competitors?
Direct peers on record are Norgine, Almirall, Recordati, Dr. Falk Pharma, Vifor Pharma and Swedish Orphan Biovitrum (Sobi). Broad incumbents are Shire (now Takeda) and Ipsen. Emerging players are Cosmo Pharmaceuticals and Stallergenes Greer.
Does SpePharm have an API?
No public API is recorded for SpePharm.